Upgrade to SI Premium - Free Trial

Stifel Reiterates Buy Rating on Dyne Therapeutics (DYN)

September 30, 2026 10:00 AM
Stifel analyst Paul Matteis reiterated a Buy rating and $37.00 price target on Dyne Therapeutics (NASDAQ: DYN).The analyst commented, "We're ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments